Guoming Zhou1, Xiangyu Jin1, Ping Zhu1, J U Yao2, Yingxin Zhang2, Lesheng Teng3, Robert J Lee4, Xiaomin Zhang5, Wei Hong6. 1. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P.R. China. 2. Hangzhou Push-Kang Biotechnology Co., Ltd., Hangzhou, Zhejiang, P.R. China. 3. College of Life Sciences, Jilin University, Changchun, Jilin, P.R. China. 4. College of Life Sciences, Jilin University, Changchun, Jilin, P.R. China Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, U.S.A. 5. Hangzhou Push-Kang Biotechnology Co., Ltd., Hangzhou, Zhejiang, P.R. China czj100007@hotmail.com bjf0915@126.com. 6. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P.R. China czj100007@hotmail.com bjf0915@126.com.
Abstract
BACKGROUND: Due to use of Tween-80 as an enhancer of solubility, the current clinical formulation of cabazitaxel (CBT) (Jevtana®) causes hypersensitivity, neurotoxicity and other severe side-effects. To reduce these vehicle-related effects, a suitable nanocarrier is needed. MATERIALS AND METHODS: Human serum albumin (HSA) was used to encapsulate CBT by a simple self-assembly method. Physicochemical properties of HSA-CBT nanoparticles were characterized. In vitro release property and cytotoxicity were also determined. In vivo imaging system was used to study nanocarrier distribution in vivo. The safety profile was assessed by hemolysis and acute-toxicity study. Finally, the antitumor efficacy in vivo was investigated in tumor-bearing mice. RESULTS: The average size of HSA-CBT nanoparticles was about 240 nm and the encapsulation efficiency reached 97%. The hemolysis and acute-toxicity experiments confirmed biocompatibility of HSA-CBT nanoparticles. CONCLUSION: HSA nanoparticles are a safe and effective drug delivery system for hydrophobic anticancer drugs such as CBT. Copyright
BACKGROUND: Due to use of Tween-80 as an enhancer of solubility, the current clinical formulation of cabazitaxel (CBT) (Jevtana®) causes hypersensitivity,neurotoxicity and other severe side-effects. To reduce these vehicle-related effects, a suitable nanocarrier is needed. MATERIALS AND METHODS:Humanserum albumin (HSA) was used to encapsulate CBT by a simple self-assembly method. Physicochemical properties of HSA-CBT nanoparticles were characterized. In vitro release property and cytotoxicity were also determined. In vivo imaging system was used to study nanocarrier distribution in vivo. The safety profile was assessed by hemolysis and acute-toxicity study. Finally, the antitumor efficacy in vivo was investigated in tumor-bearing mice. RESULTS: The average size of HSA-CBT nanoparticles was about 240 nm and the encapsulation efficiency reached 97%. The hemolysis and acute-toxicity experiments confirmed biocompatibility of HSA-CBT nanoparticles. CONCLUSION: HSA nanoparticles are a safe and effective drug delivery system for hydrophobic anticancer drugs such as CBT. Copyright
Authors: Amber Gonda; Nanxia Zhao; Jay V Shah; Hannah R Calvelli; Harini Kantamneni; Nicola L Francis; Vidya Ganapathy Journal: Med One Date: 2019-09-30